Relighting Photosensitizers by Synergistic Integration of Albumin and Perfluorocarbon for Enhanced Photodynamic Therapy

详细信息    查看全文

• 作者：Hao Ren ; Jiaqi Liu ; Fenhong Su ; Sizhan Ge ; Ahu Yuan ; Weimin Dai ; Jinhui WuYiqiao Hu
• 刊名：ACS Applied Materials & Interfaces
• 出版年：2017
• 出版时间：February 1, 2017
• 年：2017
• 卷：9
• 期：4
• 页码：3463-3473
• 全文大小：841K
• ISSN：1944-8252

文摘

Photodynamic therapy (PDT) is hampered by poor water solubility and skin phototoxicity of photosensitizers (PSs). Incorporation of PSs into nanocarrier (Nano-PDT) has been designed to overcome these problems. However, self-quenching of PSs highly condensed in Nano-PDT significantly reduced singlet oxygen (¹O₂) generation, resulting in unsatisfactory PDT efficacy. Here, we developed a novel tripleffect Nano-PDT, which has a special core–shell nanostructure by synergistic integration of perfluorotributylamine (PFTBA) and human serum albumin (HSA) to improve PDT. It has three mechanisms to relight quenched PSs, thereby generating more ¹O₂. First, PSs uniformly dispersed in the shell, preventing self-quenching caused by π–π stacking. Second, HSA as nanocarrier extends the triplet-state lifetimes of PSs, increasing the amount of ¹O₂. Third, PFTBA as core dissolves and protects¹ O₂ to extend the duration time of action of ¹O₂. Compared with PS-encapsulated Nano-PDT, the self-quenching of PSs in tripleffect Nano-PDT can be effectively overcome. The fluorescence and ¹O₂ generation of PS are increased by approximately 100-fold and 15-fold, respectively. After intravenous injection into tumor-bearing mice, the tumor growth is significantly inhibited, while the PS-encapsulated Nano-PDT has almost no effect. The novel tripleffect Nano-PDT may guide improvement of existing clinical PDT and future PDT design.